

**TOXICOLOGICAL PROFILE FOR
BERYLLIUM**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2002

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6** **How Can (Chemical X) Affect Children?**
- Section 1.7** **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7** **Children's Susceptibility**
- Section 6.6** **Exposures of Children**

Other Sections of Interest:

- Section 3.8** **Biomarkers of Exposure and Effect**
 - Section 3.11** **Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 **Fax:** (404) 498-0057
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies. *Managing Hazardous Materials Incidents*

is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Cassandra Smith, M.S.
ATSDR, Division of Toxicology, Atlanta, GA

Lisa Ingerman, Ph.D., DABT
Syracuse Research Corporation, North Syracuse, NY

Richard Amata, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for beryllium. The panel consisted of the following members:

1. Dr. Derek J. Hodgson, University of Nebraska at Omaha, Omaha, NE.
2. Dr. Laurence Holland, Private Consultant, Los Alamos, NM.
3. Dr. Hanspeter Witschi, Center for Health and the Environment, University of California Davis, CA 95615.
4. Dr. Finis Cavendar, Adjunct Professor, Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

These experts collectively have knowledge of beryllium's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS BERYLLIUM?	1
1.2 WHAT HAPPENS TO BERYLLIUM WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO BERYLLIUM?	4
1.4 HOW CAN BERYLLIUM ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN BERYLLIUM AFFECT MY HEALTH?	6
1.6 HOW CAN BERYLLIUM AFFECT CHILDREN?	7
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO BERYLLIUM?	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO BERYLLIUM?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH ?	9
1.10 WHERE CAN I GET MORE INFORMATION?	10
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO BERYLLIUM IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	11
2.3 MINIMAL RISK LEVELS	16
3. HEALTH EFFECTS	19
3.1 INTRODUCTION	19
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	19
3.2.1 Inhalation Exposure	21
3.2.1.1 Death	21
3.2.1.2 Systemic Effects	23
3.2.1.3 Immunological and Lymphoreticular Effects	62
3.2.1.4 Neurological Effects	64
3.2.1.5 Reproductive Effects	64
3.2.1.6 Developmental Effects	64
3.2.1.7 Cancer	65
3.2.2 Oral Exposure	73
3.2.2.1 Death	74
3.2.2.2 Systemic Effects	74
3.2.2.3 Immunological and Lymphoreticular Effects	85

3.2.2.4	Neurological Effects	86
3.2.2.5	Reproductive Effects	86
3.2.2.6	Developmental Effects	87
3.2.2.7	Cancer	87
3.2.3	Dermal Exposure	88
3.2.3.1	Death	88
3.2.3.2	Systemic Effects	88
3.2.3.3	Immunological and Lymphoreticular Effects	89
3.2.3.4	Neurological Effects	90
3.2.3.5	Reproductive Effects	90
3.2.3.6	Developmental Effects	90
3.2.3.7	Cancer	90
3.2.4	Other Routes of Exposure	90
3.3	GENOTOXICITY	94
3.4	TOXICOKINETICS	96
3.4.1	Absorption	96
3.4.1.1	Inhalation Exposure	96
3.4.1.2	Oral Exposure	96
3.4.1.3	Dermal Exposure	97
3.4.2	Distribution	97
3.4.2.1	Inhalation Exposure	98
3.4.2.2	Oral Exposure	99
3.4.2.3	Dermal Exposure	99
3.4.2.4	Other Routes of Exposure	99
3.4.3	Metabolism	100
3.4.4	Elimination and Excretion	100
3.4.4.1	Inhalation Exposure	100
3.4.4.2	Oral Exposure	102
3.4.4.3	Dermal Exposure	102
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/ Pharmacodynamic (PD) Models	102
3.5	MECHANISMS OF ACTION	105
3.5.1	Pharmacokinetic Mechanisms	105
3.5.2	Mechanisms of Toxicity	105
3.5.3	Animal-to-Human Extrapolations	107
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	107
3.7	CHILDREN'S SUSCEPTIBILITY	109
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	111
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Beryllium	112
3.8.2	Biomarkers Used to Characterize Effects Caused by Beryllium	115
3.9	INTERACTIONS WITH OTHER CHEMICALS	116
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	117
3.11	METHODS FOR REDUCING TOXIC EFFECTS	119
3.11.1	Reducing Peak Absorption Following Exposure	120
3.11.2	Reducing Body Burden	120
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	121
3.12	ADEQUACY OF THE DATABASE	122
3.12.1	Existing Information on Health Effects of Beryllium	123
3.12.2	Identification of Data Needs	125
3.12.3	Ongoing Studies	134

4. CHEMICAL AND PHYSICAL INFORMATION	137
4.1 CHEMICAL IDENTITY	137
4.2 PHYSICAL AND CHEMICAL PROPERTIES	137
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	143
5.1 PRODUCTION	143
5.2 IMPORT/EXPORT	144
5.3 USE	144
5.4 DISPOSAL	147
6. POTENTIAL FOR HUMAN EXPOSURE	149
6.1 OVERVIEW	149
6.2 RELEASES TO THE ENVIRONMENT	151
6.2.1 Air	152
6.2.2 Water	157
6.2.3 Soil	158
6.3 ENVIRONMENTAL FATE	159
6.3.1 Transport and Partitioning	159
6.3.2 Transformation and Degradation	161
6.3.2.1 Air	161
6.3.2.2 Water	161
6.3.2.3 Sediment and Soil	164
6.3.2.4 Other Media	164
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	164
6.4.1 Air	164
6.4.2 Water	165
6.4.3 Sediment and Soil	166
6.4.4 Other Environmental Media	169
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	173
6.6 EXPOSURES OF CHILDREN	175
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	177
6.8 ADEQUACY OF THE DATABASE	178
6.8.1 Identification of Data Needs	178
6.8.2 Ongoing Studies	181
7. ANALYTICAL METHODS	183
7.1 BIOLOGICAL MATERIALS	183
7.2 ENVIRONMENTAL SAMPLES	186
7.3 ADEQUACY OF THE DATABASE	190
7.3.1 Identification of Data Needs	190
7.3.2 Ongoing Studies	191
8. REGULATIONS AND ADVISORIES	193
9. REFERENCES	201
10. GLOSSARY	241

APPENDICES

ATSDR MINIMAL RISK LEVELS AND WORKSHEETS A-1

USER’S GUIDE B-1

ACRONYMS, ABBREVIATIONS, AND SYMBOLS C-1

INDEX D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Beryllium - Inhalation	41
3-2. Levels of Significant Exposure to Beryllium - Oral	79
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	104
3-4. Relationship Between Urine Level of Beryllium and Air Concentration	114
3-5. Existing Information on Health Effects of Beryllium	124
6-1. Frequency of NPL Sites With Beryllium Contamination	150

LIST OF TABLES

3-1. Levels of Significant Exposure to Beryllium - Inhalation	24
3-2. Levels of Significant Exposure to Beryllium - Oral	75
3-3. Levels of Significant Exposure to Beryllium - Dermal	91
3-4. Genotoxicity of Beryllium and Its Compounds <i>In Vitro</i>	95
3-5. Histologic Characteristics of Beryllium-induced Disease in Mice and Humans	108
3-6. Ongoing Studies on Beryllium	135
4-1. Chemical Identity of Beryllium and Beryllium Compounds	138
4-2. Physical and Chemical Properties of Beryllium and Beryllium Compounds	140
5-1. Facilities that Produce, Process, or Use Beryllium	145
5-2. Facilities that Produce, Process, or Use Beryllium Compounds	146
6-1. Anthropogenic and Natural Emissions of Beryllium and Beryllium Compounds to the Atmosphere	153
6-2. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium	154
6-3. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium Compounds	155
6-4. Precipitation of Beryllium Compounds in a Neutral (pH 6.5–9.5) Environment	162
6-5. Beryllium Content of Drinking Water	167
6-6. Beryllium Content of Various Fresh Foods	170
6-7. Beryllium Content of Various Fruits and Fruit Juices	172
6-8. Ongoing Studies on Human Exposure to Beryllium	182
7-1. Analytical Methods for Determining Beryllium in Biological Materials	184
7-2. Analytical Methods for Determining Beryllium in Environmental Samples	187
8-1. Regulations and Guidelines Applicable to Beryllium	195

